Investor Presentation

**1. Financial Highlights:** Q1 FY26 revenue reached ₹46.22 Cr (+14% YoY, -4% QoQ). PAT was ₹1.06 Cr (-24% YoY, +58% QoQ), with EBITDA margin at 3.80%. Cored wires generated ₹35 Cr revenue (+39% YoY volume). Aluminium Flipping Coil (₹7 Cr) operations were scaled down due to margin pressures. **2. Strategic Initiatives & Growth Drivers:** Sarthak is diversifying into cored wire, welding, and biotechnology.

Welding aims for ₹25 Cr annual sales, leveraging RDSO approval.

Biotech's 14 kg Solid State Fermentation (SSF) pilot facility is operational, planning a large-scale expansion. **3. Business Developments:** Welding division revenue hit ₹2.7 Cr in Q1 FY26 (+17% QoQ volumes), boosted by RDSO approval for Indian Railways.

Biotech's SSF pilot production commenced. **4. Market Position & Competitive Advantage:** Cored wires' technological edge pushed capacity utilization over 50%. Welding targets import substitution, gaining an advantage with RDSO approval.

Biotech explores high-demand industrial enzymes. **5. Investor Implications:** Strategic diversification in welding and biotechnology offers positive growth potential.

While the aluminum segment's scaled-down operations need monitoring, the company's focus on resilience and long-term success targets sustainable value.